|Slideshows|March 9, 2021

How to Switch Stimulants: A Dosing Guide for ADHD

Getting the dose just right can be tough...

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

ByAnn Childress, MD

July 11th 2026

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

ByAnn Childress, MD

July 10th 2026

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

ByJessica Walters

July 1st 2026

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

ByLenard A. Adler, MD

June 26th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

How to Switch Stimulants: A Dosing Guide for ADHD

Related Content

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia

The Psychiatric Impact of Cannabis Policy: More Than a Legal Framework

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH